VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 18, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB), a biotechnology company specializing in carbohydrate chemistry technology, is pleased to announce that it is has engaged Ray Matthews & Associates Inc. (RM&A) to provide corporate development and strategic advisory consulting services.
"Ray Matthews and his team have a proven track record in supporting financing efforts for several biotechnology companies," stated Dr. Howard Verrico, President & CEO of Sirona Biochem. "Ray Matthews and Associates joins Sirona Biochem at an exciting time with the company focused on partnering and commercialization. Our company will benefit from RM&A's broad range of experience in strategic planning, corporate development, investor relations and operational consultation," Dr. Verrico added.
"In our first fund (Advantage), some of our early success was due to holdings which had novel solutions addressing blockbuster markets. Sirona Biochem has a compound in development which has the potential to achieve substantial shareholder value. I am excited to be able to add value and help attract additional talent and networks to advance this program," commented Ray Matthews.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit www.sironabiochem.com.
About Ray Matthews & Associates Inc.
Ray Matthews & Associates Inc (RM&A) is a strategic advisory firm focusing on corporate development, M&A, strategic planning and boutique IR services to Canadian and U.S.-based companies at all stages of development. For more information on RM&A Inc, please visit www.raymatthews.ca.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.